Registered for use in New Zealand, each millilitre (mL) of Oxapex contains 65 mg hemoglobin betafumaril (bovine), obtained from cattle in New Zealand, a country with a negligible risk for Bovine Spongiform Encephalopathy1,2. The haemoglobin extracted from the bovine whole blood is then processed in GMP certified facilities to make Oxapex. The unique features of Oxapex, including rapid restoration of tissue oxygenation, readiness of administration, superior shelf life and reliable safety profile, enable it to be used extensively in clinical settings. It is registered for use as a one-time administration by intravenous infusion, with a recommended dose of 5-30 mL/kg of body weight, delivered at the rate of 10 mL/kg/hour2.
- Data on file.
- Oxapex® prescribing information. New Alpha Innovation New Zealand Limited. Version 2020.